These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15744234)

  • 1. gammadelta T cells: a new frontier for immunotherapy?
    Lamb LS; Lopez RD
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response.
    Lamb LS; Musk P; Ye Z; van Rhee F; Geier SS; Tong JJ; King KM; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Mar; 27(6):601-6. PubMed ID: 11319589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).
    Smetak M; Kimmel B; Birkmann J; Schaefer-Eckart K; Einsele H; Wilhelm M; Kunzmann V
    Bone Marrow Transplant; 2008 Apr; 41(7):643-50. PubMed ID: 18037935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry.
    Olin MR; Hwa Choi K; Lee J; Molitor TW
    J Immunol Methods; 2005 Feb; 297(1-2):1-11. PubMed ID: 15777926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
    van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
    Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
    Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
    Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.